In February, 2021, Fierce Pharma released its report of the 10 most-anticipated drug launches of 2021, which ranks drugs based on predicted global sales through 2026. The report’s most anticipated drug is aducanumab, which is produced by Biogen and Eisai for the treatment of Alzheimer’s disease. The drug’s release, however, is still awaiting approval – or rejection – by the U.S. Food and Drug Administration (FDA). There is significant debate over whether the drug makes a difference in Alzheimer patients